Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with ...
Boosting survival in advanced urothelial carcinoma: The power of CBM588 probiotic and pembrolizumab combination. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results